Does topical finasteride work as well as oral?

A Phase III trial found topical finasteride 0.25% spray produced comparable hair count improvements to oral 1mg over 24 weeks. The main difference is systemic DHT suppression: approximately 4% for topical vs 65% for oral.

Is topical finasteride FDA-approved?

No. Topical finasteride is not FDA-approved. It is available only as a compounded product from compounding pharmacies and is not subject to the same FDA manufacturing and quality oversight as approved drugs.

Does topical finasteride have fewer side effects than oral?

The Phase III trial reported fewer sexual adverse events in the topical group than the oral group, consistent with lower systemic DHT suppression. However, the trial was only 24 weeks. Long-term side effect comparisons are not available.

How is topical finasteride applied?

The Phase III trial used a 0.25% spray applied to the scalp. Compounded formulations vary in concentration (typically 0.1-1%) and vehicle. Application is typically once daily to the scalp. Instructions vary by formulation.

Can I get topical finasteride without a prescription?

No. Finasteride in any form requires a prescription in the United States. Topical finasteride must be obtained through a licensed compounding pharmacy with a valid prescription.

Is topical or oral finasteride better?

Both produce comparable hair regrowth based on trial data. The trade-off is: oral has FDA approval, decades of safety data, and established quality standards; topical has lower systemic exposure but is not FDA-approved, and quality varies by compounder. Discuss with a dermatologist based on your priorities.

Does Topical Finasteride Work for Hair Loss?

Last updated: Apr 20, 2026Fact CheckTopical FinasterideBased on 3 studies

This is a research-based fact check, not medical advice. The findings summarized here come from peer-reviewed studies and are presented without added opinions. Consult a certified healthcare practitioner before making any treatment decision.

Verdict

Yes, topical finasteride works for hair loss based on a Phase III randomised controlled trial. A 24-week trial of 458 men found topical finasteride 0.25% spray increased target area hair count by 20.2 hairs vs placebo (significant). Efficacy was comparable to oral finasteride 1mg. Serum DHT suppression was approximately 4-15% vs 65% for oral, suggesting substantially lower systemic exposure. Topical finasteride is not FDA-approved and is available only through compounding pharmacies.

Key takeaways

Topical finasteride is NOT FDA-approved for hair loss and is available only as a compounded product.
A Phase III trial (458 men, 24 weeks) found it increased hair count by 20.2 vs placebo and was comparable to oral finasteride.
Serum DHT suppression is approximately 4-15% vs 65% for oral finasteride suggesting far lower systemic exposure.
Lower systemic DHT suppression is hypothesised to reduce systemic side effects including sexual dysfunction.
FDA issued an adverse event communication in 2025 regarding compounded finasteride formulations.
Efficacy data is less mature than for oral finasteride, which has decades of controlled trial data.

Topical finasteride is not FDA-approved for hair loss. It is a compounded medication. The FDA has not reviewed or approved its safety and efficacy. In 2025, the FDA issued an adverse event communication regarding compounded finasteride products.

Clinical evidence

The pivotal evidence for topical finasteride comes from a Phase III, randomised, double-blind, double-dummy, parallel-group 24-week trial in 458 men with androgenetic alopecia at 45 sites in Europe (Piraccini et al. 2021). The primary endpoint was change from baseline in target area hair count at week 24. Topical finasteride 0.25% spray produced an adjusted mean change of +20.2 hairs vs placebo (statistically significant). Oral finasteride 1mg was the reference arm; results were comparable between topical and oral. For context on all finasteride options, see the hair restoration guide and our topical vs oral finasteride comparison.

DHT suppression and systemic exposure

A key finding of the Phase III trial was that topical finasteride produced approximately 4% suppression of serum DHT compared to approximately 65% for oral finasteride. This is a 16-fold difference in systemic DHT impact. The hypothesis is that topical application concentrates finasteride in scalp tissue where it is needed, while limiting systemic absorption and the systemic side effects associated with oral use. Scalp DHT levels were reduced more substantially than serum DHT, suggesting local pharmacological action.

Sexual side effects and systemic safety

The Phase III trial reported a similar frequency of sexual adverse events between topical finasteride and placebo groups, and a lower frequency than the oral finasteride group, consistent with the lower systemic DHT suppression. However, the trial was only 24 weeks and may not be powered to detect differences in rare side effects. Post-market evidence on long-term sexual side effect rates for topical finasteride is limited. The 2025 FDA adverse event communication should be reviewed for any updated safety data.

Regulatory status

Topical finasteride is not FDA-approved. It is available only through compounding pharmacies in the United States. Compounded products are not reviewed by the FDA for safety, efficacy, or manufacturing quality in the same way as approved drugs. Quality and concentration can vary between compounders.

Study	Patients	Key finding
Piraccini 2022: topical finasteride 0.25% Phase III trial	Phase III RCT (n=458, 24 wks)	Topical finasteride increased hair count by 20.2 vs placebo. Comparable to oral 1mg. Serum DHT suppression approximately 4% vs 65% for oral.
Lee 2018: topical finasteride systematic review	Systematic review	Topical finasteride shows efficacy in hair loss. Lower systemic exposure than oral confirmed across studies.
Yu 2026: topical finasteride and minoxidil safety	Safety review	Safety profile of topical finasteride with minoxidil combination reviewed.

What the research cannot tell you

Long-term efficacy and safety beyond 24 weeks in the Phase III trial.
Whether the reduction in serum DHT suppression translates to lower rates of post-finasteride syndrome.
Efficacy variation between different compounded formulations (concentration, vehicle, delivery method).
Whether topical finasteride combined with minoxidil produces superior results to oral finasteride plus minoxidil.